Orthopaedic and Traumatology Division, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Italy.
J Biol Regul Homeost Agents. 2020 Sep-Oct;34(5 Suppl. 1):57-62. IORS Special Issue on Orthopedics.
Giant cell tumour (GCT) represents 5% of all primitive bone tumours. Standard surgical treatment of GCT includes intralesional excision or segmental resection. Curettage has a higher recurrence rate (10-25% in stage 2 or 3 but does preserve adjacent joint function. The use of local adjuvants such as phenol, alcohol, H2O2, Argon or cement may decrease recurrence rate, yet which local adjuvant works best is still, to this day, controversial. A series of 109 patients with GCT of the extremity, surgical treated in a single Institution from 2016 to 2018, were analysed in a retrospective study. The purpose of our study was to report the incidence of recurrence rate in patients with GCT of limbs treated in a single institution with different local adjuvants. The results of the present study suggests that curettage in association to cryoablation seems to reduce the recurrence rate compared to "classic" local adjuvants.
巨细胞瘤(GCT)占所有原发性骨肿瘤的 5%。GCT 的标准手术治疗包括病灶内切除术或节段切除术。刮除术的复发率较高(2 期或 3 期为 10-25%,但可保留相邻关节功能。局部辅助剂如苯酚、酒精、H2O2、氩气或水泥的使用可能会降低复发率,但哪种局部辅助剂效果最好,至今仍存在争议。本研究回顾性分析了 2016 年至 2018 年在一家机构接受手术治疗的 109 例肢体 GCT 患者。本研究的目的是报告在一家机构中使用不同局部辅助剂治疗肢体 GCT 患者的复发率。本研究结果表明,与“经典”局部辅助剂相比,刮除术联合冷冻消融似乎可以降低复发率。